Nxera Pharma (4565) Status Update summary

Strategic Vision and Growth Targets

• Aims to become a top Japanese pharma by 2030, targeting JPY 50 billion in revenue and at least five product launches in Japan, with a 26% CAGR from FY2023 results.

• Focuses on neurology, metabolism, immunology, and rare diseases, with continued investment in talent, technology, and business process improvements.

• Strategic expansion includes a global technical operations hub in Switzerland, acquisition of Idorsia's Japan and Korea businesses, and APAC growth through licensing and acquisitions.

• Over 20 product opportunities identified, each with peak sales potential between JPY 15-50 billion, with several in contract discussions.

• Mission to accelerate medicine from Japan for global impact, leveraging technology and continuous process improvement.

Product and Pipeline Updates

• PIVLAZ, for post-aSAH cerebral vasospasm, reached 66% market share in Japan and is expected to generate JPY 15-16 billion in revenue, with expansion to Korea planned for 2025-2026.

• QUVIVIQ, a dual orexin receptor antagonist for insomnia, recently approved in Japan, will be marketed exclusively by Shionogi, with expected peak sales over JPY 20 billion and net sales royalties above JPY 4 billion.

• Pipeline includes NBI-568 (M4 agonist) moving to phase III for schizophrenia, ORX750 (OX2 agonist) in phase II for narcolepsy, and NXE'149 (GPR52 agonist) optioned to Boehringer Ingelheim.

• NXE-744 (EP4 agonist) in phase I for IBD, and NXE-732 (EP4 antagonist) in phase I/IIa for solid tumors, showing strong synergy with checkpoint inhibitors.

• At least three new products expected to launch by 2030, fueling the JPY 50 billion revenue target and long-term innovation pipeline.

R&D Platform and Partnerships

• NxWave platform enables structure-based drug discovery, focusing on GPCRs, with 26 preclinical and 17 clinical candidates identified to date.

• Partnerships with Neurocrine, Centessa, Boehringer Ingelheim, Lilly, AbbVie, Genentech, and Pfizer have advanced multiple clinical programs, generating significant milestone revenues.

• New collaborations include PrecisionLife for AI-driven target discovery in autoimmune diseases and Antiverse for next-generation antibody therapeutics against GPCRs.

• AI-driven and phenotypic screening approaches are expanding the discovery of next-generation GPCR targets across multiple disease areas.

• In-house and partnered pipelines target major indications in neuroscience, metabolism, immunology, and oncology, aiming to impact over 500 million patients globally.